Value proposition

Octavian develops non-addictive small-molecule medicines targeting the ECS to revolutionise precision pain management.

Octavian is at the frontier of precision pain management, developing innovative, non-addictive, small-molecule medicines that target the endocannabinoid system (ECS) to address the global challenge of chronic pain, which affects over 1.5 billion 1 people and drives dangerous dependence on opioids.